Purpose: The specific aims of this paper are to (1) develop and operationalize an electronic health record (EHR) data quality framework, (2) apply the dimensions of the framework to the phenotype and treatment pathways of ductal carcinoma in situ (DCIS) using Research Program data, and (3) propose and apply a checklist to evaluate the application of the framework.
Methods: We developed a framework of five data quality dimensions (DQD; completeness, concordance, conformance, plausibility, and temporality). Participants signed a consent and Health Insurance Portability and Accountability Act authorization to share EHR data and responded to demographic questions in the Basics questionnaire. We evaluated the internal characteristics of the data and compared data with external benchmarks with descriptive and inferential statistics. We developed a DQD checklist to evaluate concept selection, internal verification, and external validity for each DQD. The Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) concept ID codes for DCIS were used to select a cohort of 2,209 females 18 years and older.
Results: Using the proposed DQD checklist criteria, (1) concepts were selected and internally verified for conformance; (2) concepts were selected and internally verified for completeness; (3) concepts were selected, internally verified, and externally validated for concordance; (4) concepts were selected, internally verified, and externally validated for plausibility; and (5) concepts were selected, internally verified, and externally validated for temporality.
Conclusion: This assessment and evaluation provided insights into data quality for the DCIS phenotype using EHR data from the Research Program. The review demonstrates that salient clinical measures can be selected, applied, and operationalized within a conceptual framework and evaluated for fitness for use by applying a proposed checklist.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1200/CCI.24.00052 | DOI Listing |
PLoS One
January 2025
Animal and Human Health Department, International Livestock Research Institute, Nairobi, Kenya.
Non-conformance with antibiotic withdrawal period guidelines represents a food safety concern, with potential for antibiotic toxicities and allergic reactions as well as selecting for antibiotic resistance. In the Kenyan domestic pig market, conformance with antibiotic withdrawal periods is not a requirement of government legislation and evidence suggests that antibiotic residues may frequently be above recommended limits. In this study, we sought to explore enablers of and barriers to conformance with antibiotic withdrawal periods for pig farms supplying a local independent abattoir in peri-urban Nairobi.
View Article and Find Full Text PDFBr J Dermatol
January 2025
Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Background: The prevalence and burden of atopic dermatitis (AD) are disproportionately high in individuals with skin of colour (SOC). Previous research shows that risk for xerosis and/or dyspigmentation is heightened in this population and may be more bothersome. However, there are no patient-reported instruments developed specifically for these disease sequelae in patients with SOC.
View Article and Find Full Text PDFNeuro Oncol
January 2025
Childhood Cancer & Cell Death team (C3 team), Consortium South-ROCK, LabEx DEVweCAN, Institut Convergence Plascan, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, 69008 Lyon, France.
Background: Brain tumors are the deadliest solid tumors in children and adolescents. Most of these tumors are glial in origin and exhibit strong heterogeneity, hampering the development of effective therapeutic strategies. In the past decades, patient-derived tumor organoids (PDT-O) have emerged as powerful tools for modeling tumoral cell diversity and dynamics, and they could then help defining new therapeutic options for pediatric brain tumors.
View Article and Find Full Text PDFClin Pharmacokinet
January 2025
Department of Clinical Pharmacology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
The rise in global obesity prevalence has increased the need to understand the pharmacokinetics of drugs in overweight and obese individuals. Tuberculosis remains a significant health challenge, and its treatment outcomes can be influenced by the pharmacokinetic profiles of antitubercular agents. This literature review aims to point out the clinical pharmacokinetics of antitubercular drugs in the overweight and obese patient population, highlighting considerations for potential dosage adjustments.
View Article and Find Full Text PDFTheor Appl Genet
January 2025
CSIRO Agriculture and Food, Canberra, ACT, 2601, Australia.
Zebularine-treated wheat uncovered a phenotype with characteristics of an epigenetically regulated trait, but major chromosomal aberrations, not DNA methylation changes, are the cause, making zebularine unsuitable for epigenetic breeding. Breeding to identify disease-resistant and climate-tolerant high-yielding wheats has led to yield increases over many years, but new hardy, higher yielding varieties are still needed to improve food security in the face of climate change. Traditional breeding to develop new cultivars of wheat is a lengthy process taking more than seven years from the initial cross to cultivar release.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!